Scholarlink

Background <p>The emergence of multidrug-resistant <i>Enterococcus faecium</i>, particularly vancomycin-resistant strains (VRE), poses a significant global health threat and necessitates novel therapeutic strategies. <i>Akkermansia muciniphila</i>, a beneficial gut commensal, is a promising next-generation probiotic with antimicrobial properties. This study aimed to evaluate the antibacterial and antivirulence efficacy of <i>A. muciniphila</i> extract against clinical <i>E. faecium</i> isolates.</p> Methods <p>Sixty urine and fecal samples were collected from the Iraqi Hospital (October 2024 to February 2025). Fifteen clinical <i>E. faecium</i> isolates were confirmed by VITEK and 16&#xa0;S rRNA sequencing. The presence of <i>ace</i> (adhesion) and <i>esp</i> (biofilm) virulence genes was determined using PCR. The antimicrobial activity of commercial <i>A. muciniphila</i> extract was assessed using agar well diffusion and broth microdilution to determine the Minimum Inhibitory Concentration (MIC). The effect of the extract on <i>ace</i> and <i>esp</i> gene expression was quantified by quantitative real-time PCR (qRT-PCR).</p> Results <p><i>Ace</i> and esp were detected in all 15 and <i>esp</i> in 13 strains, respectively. The <i>A. muciniphila</i> extract demonstrated significant growth inhibition, with an MIC of 6.25&#xa0;mg/mL. Sub-inhibitory concentrations of the extract resulted in a significant downregulation of virulence gene expression, with ace expression reduced by up to 7.14-fold and <i>esp</i> expression reduced by up to 250-fold compared to the untreated controls (<i>P</i> &lt; 0.05).</p> Conclusions <p><i>A. muciniphila</i> extract inhibited the growth of <i>E. faecium</i> and reduced the expression of virulence genes (<i>ace/esp</i>), suggesting potential therapeutic efficacy against drug-resistant infections. However, additional mechanistic studies and <i>in vivo</i> confirmation are required for clinical applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of the antibacterial activity of Akkermansia muciniphila extract against Enterococcus faecium isolates

  • 期刊论文

  • 发表日期：

    2026年1月24日

查看全文
  • Mokhtar Jawad Kadhim,
  • Marwa H. AlKhafaji,
  • Hiba Hazim Hamid

摘要

Background

The emergence of multidrug-resistant Enterococcus faecium, particularly vancomycin-resistant strains (VRE), poses a significant global health threat and necessitates novel therapeutic strategies. Akkermansia muciniphila, a beneficial gut commensal, is a promising next-generation probiotic with antimicrobial properties. This study aimed to evaluate the antibacterial and antivirulence efficacy of A. muciniphila extract against clinical E. faecium isolates.

Methods

Sixty urine and fecal samples were collected from the Iraqi Hospital (October 2024 to February 2025). Fifteen clinical E. faecium isolates were confirmed by VITEK and 16 S rRNA sequencing. The presence of ace (adhesion) and esp (biofilm) virulence genes was determined using PCR. The antimicrobial activity of commercial A. muciniphila extract was assessed using agar well diffusion and broth microdilution to determine the Minimum Inhibitory Concentration (MIC). The effect of the extract on ace and esp gene expression was quantified by quantitative real-time PCR (qRT-PCR).

Results

Ace and esp were detected in all 15 and esp in 13 strains, respectively. The A. muciniphila extract demonstrated significant growth inhibition, with an MIC of 6.25 mg/mL. Sub-inhibitory concentrations of the extract resulted in a significant downregulation of virulence gene expression, with ace expression reduced by up to 7.14-fold and esp expression reduced by up to 250-fold compared to the untreated controls (P < 0.05).

Conclusions

A. muciniphila extract inhibited the growth of E. faecium and reduced the expression of virulence genes (ace/esp), suggesting potential therapeutic efficacy against drug-resistant infections. However, additional mechanistic studies and in vivo confirmation are required for clinical applications.